{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:55:56Z","timestamp":1790906156010,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00927"],"award-info":[{"award-number":["PI19\/00927"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Emerald Health Biotechnology Espa\u00f1a","award":["JMO.Mo1EHBE"],"award-info":[{"award-number":["JMO.Mo1EHBE"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl. Stroke Res."],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12975-022-01017-4","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T22:02:44Z","timestamp":1649887364000},"page":"397-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Neuroprotective Efficacy of Betulinic Acid Hydroxamate, a B55\u03b1\/PP2A Activator, in Acute Hypoxia\u2013Ischemia-Induced Brain Damage in Newborn Rats"],"prefix":"10.1007","volume":"14","author":[{"given":"Laura","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Prados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Diego","family":"Unciti-Broceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mart\u00ednez-Orgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"1017_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpeds.2017.08.031","volume":"192","author":"P Parikh","year":"2018","unstructured":"Parikh P, Juul SE. Neuroprotective strategies in neonatal brain injury. J Pediatr. 2018;192:22\u201332.","journal-title":"J Pediatr"},{"key":"1017_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2008.07.003","volume":"120","author":"FF Gonzalez","year":"2008","unstructured":"Gonzalez FF, Ferriero DM. Therapeutics for neonatal brain injury. Pharmacol Ther. 2008;120:43\u201353.","journal-title":"Pharmacol Ther"},{"key":"1017_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S1474-4422(11)70016-3","volume":"10","author":"MV Johnston","year":"2011","unstructured":"Johnston MV, Fatemi A, Wilson MA, Northington F. Treatment advances in neonatal neuroprotection and neurointensive care. Lancet Neurol. 2011;10:372\u201382.","journal-title":"Lancet Neurol"},{"key":"1017_CR4","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/jama.2017.14972","volume":"318","author":"AR Laptook","year":"2017","unstructured":"Laptook AR, Shankaran S, Tyson JE, Munoz B, Bell EF, Goldberg RN, et al. Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy a randomized clinical trial. JAMA. 2017;318:1550\u201360.","journal-title":"JAMA"},{"key":"1017_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.brainresrev.2009.09.006","volume":"31","author":"X Fan","year":"2009","unstructured":"Fan X, Heijnen CJ, van der Kooij MA, Groenendaal F, van Bel F. The role and regulation of hypoxia-inducible factor-1\u03b1 expression in brain development and neonatal hypoxic-ischemic brain injury. Brain Res Rev. 2009;31:99\u2013108.","journal-title":"Brain Res Rev"},{"key":"1017_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.braindev.2009.03.007","volume":"31","author":"R Trollmann","year":"2009","unstructured":"Trollmann R, Gassmann M. The role of hypoxia-inducible transcription factors in the hypoxic neonatal brain. Brain Dev. 2009;31:503\u20139.","journal-title":"Brain Dev"},{"key":"1017_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11064-015-1641-y","volume":"41","author":"HX Chu","year":"2016","unstructured":"Chu HX, Jones NM. Changes in hypoxia-inducible factor-1 (HIF-1) and regulatory prolyl hydroxylase (PHD) enzymes following hypoxic\u2013ischemic injury in the neonatal rat. Neurochem Res. 2016;41:515\u201322.","journal-title":"Neurochem Res"},{"key":"1017_CR8","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.2741\/2892","volume":"13","author":"A Siddiq","year":"2008","unstructured":"Siddiq A, Aminova LR, Ratan RR. Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection. Front Biosci. 2008;13:2875\u201387.","journal-title":"Front Biosci"},{"key":"1017_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/978-3-211-85578-2_77","volume":"102","author":"W Chen","year":"2008","unstructured":"Chen W, Jadhav V, Tang J, Zhang JH. HIF-1 alpha inhibition ameliorates neonatal brain damage after hypoxic-ischemic injury. Acta Neurochir Suppl. 2008;102:395\u20139.","journal-title":"Acta Neurochir Suppl"},{"key":"1017_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neuropharm.2015.07.007","volume":"99","author":"J Min","year":"2015","unstructured":"Min J, Hu J, He M, et al. Vitexin reduces hypoxia e ischemia neonatal brain injury by the inhibition of HIF-1alpha in a rat pup model. Neuropharmacology. 2015;99:38\u201350.","journal-title":"Neuropharmacology"},{"key":"1017_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jnc.14822","volume":"150","author":"O Vetrovoy","year":"2019","unstructured":"Vetrovoy O, Rybnikova E. Neuroprotective action of PHD inhibitors is predominantly HIF-1-independent. J Neurochem. 2019;150:645\u20137.","journal-title":"J Neurochem"},{"key":"1017_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/jnc.14790","volume":"150","author":"K Li","year":"2019","unstructured":"Li K, Li T, Wang Y, et al. Sex differences in neonatal mouse brain injury after hypoxia-ischemia and adaptaquin treatment. J Neurochem. 2019;150:759\u201375.","journal-title":"J Neurochem"},{"key":"1017_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pneurobio.2013.11.005","volume":"114","author":"RA Stetler","year":"2014","unstructured":"Stetler RA, Leak RK, Gan Y, et al. Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance. Prog Neurobiol. 2014;114:58\u201383.","journal-title":"Prog Neurobiol"},{"key":"1017_CR14","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.celrep.2017.01.051","volume":"18","author":"G Di Conza","year":"2017","unstructured":"Di Conza G, TrussoCafarello S, Loroch S, et al. The mTOR and PP2A pathways regulate PHD2 phosphorylation to fine-tune HIF1\u03b1 levels and colorectal cancer cell survival under hypoxia. Cell Rep. 2017;18:1699\u2013712.","journal-title":"Cell Rep"},{"key":"1017_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/CIRCRESAHA.119.316071","volume":"127","author":"M Ehling","year":"2020","unstructured":"Ehling M, Celus W, Mart\u00edn-Perez R, et al. B55\u03b1\/PP2A limits endothelial cell apoptosis during vascular remodeling: a complementary approach To Disrupt Pathological Vessels? Circ Res. 2020;127:707\u201323.","journal-title":"Circ Res"},{"key":"1017_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/1873-3468.12907","volume":"592","author":"G Taleski","year":"2018","unstructured":"Taleski G, Sontag E. Protein phosphatase 2A and tau: an orchestrated \u201cPas de Deux.\u201d FEBS Lett. 2018;592:1079\u201395.","journal-title":"FEBS Lett"},{"key":"1017_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01089-4","author":"ME Prados","year":"2021","unstructured":"Prados ME, Correa-S\u00e1ez A, Unciti-Broceta J, et al. Betulinic acid hydroxamate is neuroprotective and induces protein phosphatase 2A-dependent HIF-1\u03b1 stabilization and post-transcriptional dephosphorylation of prolyl hydrolase 2. Neurotherapeutics. 2021. https:\/\/doi.org\/10.1007\/s13311-021-01089-4.","journal-title":"Neurotherapeutics"},{"key":"1017_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.neuropharm.2012.05.034","volume":"63","author":"MR Pazos","year":"2012","unstructured":"Pazos MR, Cinquina V, G\u00f3mez A, et al. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology. 2012;63:776\u201383.","journal-title":"Neuropharmacology"},{"key":"1017_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2019.01131","volume":"10","author":"M Cepri\u00e1n","year":"2019","unstructured":"Cepri\u00e1n M, Vargas C, Garc\u00eda-Toscano L, et al. Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats. Front Pharmacol. 2019;10:1131.","journal-title":"Front Pharmacol"},{"key":"1017_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.neuropharm.2016.12.017","volume":"116","author":"M Cepri\u00e1n","year":"2017","unstructured":"Cepri\u00e1n M, Jim\u00e9nez-S\u00e1nchez L, Vargas C, Barata L, Hind W, Mart\u00ednez-Orgado J. Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Neuropharmacology. 2017;116:151\u20139.","journal-title":"Neuropharmacology"},{"key":"1017_CR21","unstructured":"Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 3rd edition. San DiegoAcademic Press. 1996."},{"key":"1017_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.11.020","volume":"146","author":"L Barata","year":"2019","unstructured":"Barata L, Arruza L, Rodr\u00edguez M-J, et al. Neuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage. Neuropharmacology. 2019;146:1\u201311.","journal-title":"Neuropharmacology"},{"key":"1017_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","volume":"71","author":"MR Pazos","year":"2013","unstructured":"Pazos MR, Mohammed N, Lafuente H, et al. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology. 2013;71:282\u201391.","journal-title":"Neuropharmacology"},{"key":"1017_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fnins.2016.00323","volume":"10","author":"H Lafuente","year":"2016","unstructured":"Lafuente H, Pazos MR, Alvarez A, et al. Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia. Front Neurosci. 2016;10:323.","journal-title":"Front Neurosci"},{"key":"1017_CR25","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1021\/acs.jnatprod.8b00514","volume":"81","author":"A Minassi","year":"2018","unstructured":"Minassi A, Rogati F, Cruz C, et al. Triterpenoid hydroxamates as HIF prolyl hydrolase inhibitors. J Nat Prod. 2018;81:2235\u201343.","journal-title":"J Nat Prod"},{"key":"1017_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neuroscience.2014.08.019","volume":"278","author":"R Trollmann","year":"2014","unstructured":"Trollmann R, Richter M, Jung S, Walkinshaw G, Brackmann F. Pharmacologic stabilization of hypoxia-inducible transcription factors protects developing mouse brain from hypoxia-induced apoptotic cell death. Neuroscience. 2014;278:327\u201342.","journal-title":"Neuroscience"},{"key":"1017_CR27","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41401-020-0497-0","volume":"42","author":"ME Prados","year":"2021","unstructured":"Prados ME, Garc\u00eda-Mart\u00edn AG-M, Unciti-Broceta JD, et al. Betulinic acid hydroxamate prevents colonic inflammation and fibrosis in murine models of inflammatory bowel disease. Acta Pharmacol Sin. 2021;42:1124\u201338.","journal-title":"Acta Pharmacol Sin"},{"key":"1017_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bbr.2009.11.010","volume":"208","author":"B Adamcio","year":"2010","unstructured":"Adamcio B, Sperling S, Hagemeyer N, Walkinshaw G, Ehrenreich H. Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice. Behav Brain Res. 2010;208:80\u20134.","journal-title":"Behav Brain Res"},{"key":"1017_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1871527315666160927110305","volume":"16","author":"N Mohammed","year":"2017","unstructured":"Mohammed N, Ceprian M, Jimenez L, Pazos MR, Mart\u00ednez-Orgado J. Neuroprotective Effects of cannabidiol in hypoxic ischemic insult the Therapeutic Window in Newborn Mice. CNS Neurol Disord Drug Targets. 2017;16:102\u20138.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1017_CR30","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1161\/STROKEAHA.109.570325","volume":"41","author":"M Iwai","year":"2010","unstructured":"Iwai M, Stetler RA, Xing J, et al. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin following neonatal hypoxic\/ischemic brain injury Masanori. Stroke. 2010;41:1032\u20137.","journal-title":"Stroke"},{"key":"1017_CR31","first-page":"4388","volume":"55","author":"J Janowska","year":"2018","unstructured":"Janowska J, Sypecka J. Therapeutic strategies for leukodystrophic disorders resulting from perinatal asphyxia: focus on myelinating oligodendrocytes. Mol Neurobiol. 2018;55:4388\u2013402.","journal-title":"Mol Neurobiol"},{"key":"1017_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.cell.2014.04.052","volume":"158","author":"TJ Yuen","year":"2014","unstructured":"Yuen TJ, Silbereis JC, Griveau A, et al. Oligodendrocyte-encoded HIF function couples postnatal myelination and white matter angiogenesis. Cell. 2014;158:383\u201396.","journal-title":"Cell"},{"key":"1017_CR33","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jocn.2008.09.024","volume":"16","author":"S Taie","year":"2009","unstructured":"Taie S, Ono J, Iwanaga Y, Tomita S, Asaga T, Chujo K, et al. Hypoxia-inducible factor-1\u03b1 has a key role in hypoxic preconditioning. J Clin Neurosci. 2009;16:1056\u201360.","journal-title":"J Clin Neurosci"},{"key":"1017_CR34","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1046\/j.1460-9568.1999.00845.x","volume":"11","author":"M Bergeron","year":"1999","unstructured":"Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci. 1999;11:4159\u201370.","journal-title":"Eur J Neurosci"},{"key":"1017_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00004647-200204000-00003","volume":"22","author":"M Bernaudin","year":"2002","unstructured":"Bernaudin M, Nedelec AS, Divoux D, MacKenzie ET, Petit E, Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab. 2002;22:393\u2013403.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1017_CR36","first-page":"20","volume":"9","author":"M Salama","year":"2016","unstructured":"Salama M, Mohamed WM. Tau protein as a biomarker for asphyxia: a possible forensic tool? Appl Transl Genom. 2016;9:20\u20132.","journal-title":"Appl Transl Genom"}],"container-title":["Translational Stroke Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-022-01017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12975-022-01017-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-022-01017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T09:36:08Z","timestamp":1683192968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12975-022-01017-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1007\/s12975-022-01017-4","relation":{},"ISSN":["1868-4483","1868-601X"],"issn-type":[{"value":"1868-4483","type":"print"},{"value":"1868-601X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]},"assertion":[{"value":"1 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Jos\u00e9 Martinez-Orgado has a Research Agreement with Emerald Health Biotechnology Espa\u00f1a S.L.U. (C\u00f3rdoba, Spain). The other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}